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The Parkinson’s disease (PD) gene, PARK6, encodes the PTEN-induced putative
kinase 1 (PINK1) mitochondrial kinase, which provides protection against oxi-
dative stress-induced apoptosis. Given the link between glucose metabolism,
mitochondrial function and insulin secretion inb-cells, and the reported association
of PD with type 2 diabetes, we investigated the response of PINK1-deficient b-cells
to glucose stimuli to determine whether loss of PINK1 affected their function.
We find that loss of PINK1 significantly impairs the ability of mouse pancreatic
b-cells (MIN6 cells) and primary intact islets to take up glucose. This was
accompanied by higher basal levels of intracellular calcium leading to increased
basal levels of insulin secretion under low glucose conditions. Finally, we investi-
gated the effect of PINK1 deficiency in vivo and find that PINK1 knockout mice
have improved glucose tolerance. For the first time, these combined results demon-
strate that loss of PINK1 function appears to disrupt glucose-sensing leading to
enhanced insulin release, which is uncoupled from glucose uptake, and suggest a
key role for PINK1 in b-cell function.2. Introduction
Type 2 diabetes is a common metabolic disorder estimated to affect over
256 million adults worldwide [1]. The predominant mechanism underlying
this disease is insulin resistance in peripheral metabolic tissues such as
muscle, liver and adipose tissue accompanied by a relative deficit in insulin
secretion [2,3]. Under normal circumstances, the alpha (a) and beta (b) islet
cells in the pancreas monitor blood glucose levels. When an increase in blood
glucose is detected, these cells take up glucose via the GLUT2 glucose transpor-




2subsequent increase in mitochondrial substrate availability
drives the electron transport chain, increases intracellular
ATP levels and induces closure of the ATP-sensitive potas-
sium channel (Kþ-ATP) at the plasma membrane. When
the Kþ-ATP channel closes, it induces depolarization of the
plasma membrane (Vm), which activates the voltage-
dependent calcium channels and induces a calcium influx
into the cell. Increased cytosolic calcium ([Ca2þ]c) concen-
trations then stimulate the secretion of insulin which, in
turn, activates glucose transporters in insulin-sensitive cells
to allow cells and tissues throughout the body to take up
glucose as an energy source [5].
PTEN-induced putative kinase 1 (PINK1) is a mitochond-
rially targeted serine/threonine kinase which protects cells
against stress-induced apoptosis [6]. Homozygous mutations
in the PINK1 gene (PARK6) and loss of PINK1 function have
been shown to be an underlying cause of early onset autoso-
mal recessive Parkinson’s disease (PD) [7]. In previous
studies, we and others have demonstrated that loss of or
impaired PINK1 function in neurons results in a series of
mitochondrial abnormalities. These include impaired calcium
buffering capacity due to inhibition of calcium efflux in the
mitochondria, increased reactive oxygen species (ROS) pro-
duction through NADPH oxidase, reduced mitochondrial
membrane potential, inhibition of the sodium calcium
(Naþ/Ca2þ) exchanger and impaired glucose transport into
the cell [8,9]. However, we have also shown that different
cell types, i.e. muscle cells, which are highly dependent on
mitochondria, can compensate for loss of PINK1 through
increasing glycolysis which overcomes the ATP deficit and
improves cellular calcium buffering capacity [10].
Interestingly, reduced transcription of the PARK6 gene,
encoding PINK1, has been reported in type 2 diabetic
(T2DM) patients implicating PINK1 in glucose metabolism
[11]. In addition, while the PINK1 N521T variant has been
directly linked to an increased risk of developing T2DM in
a northern Chinese population [12], subsequent genome-
wide association studies have thus far not supported a role
for PINK1 as a risk factor for T2DM [13]. However, the con-
sequences of PINK1 deficiency on islet cell function and
hence the mechanism by which PINK1 dysfunction could
contribute to T2DM have yet to be investigated. We therefore
used a combination of PINK1 siRNA, primary PINK1 knock-
out (KO) intact islets and PINK1 KO mice to determine the
effect of PINK1 deficiency on b-cell function.3. Results
3.1. PINK1 is expressed in MIN6 cells and isolated
wild-type islets
To assess whether loss of PINK1 function would poten-
tially have an effect on islet cell function, we sought to
determine whether PINK1 was expressed in islet cells.
Owing to continuing problems assessing mouse PINK1 by
western blot, we assayed MIN6 cells and isolated PINK1
wild-type (WT) and KO islets for PINK1 expression by RT-
PCR. PINK1 WT mouse midbrain (known to express high
levels of PINK1) was used as a control. Figure 1a demon-
strates that PINK1 transcripts are present in both MIN6
cells and isolated WT islets, but these levels are significantlyreduced by comparison with transcript levels in the midbrain
(n ¼ 4, *p , 0.01 and **p , 0.0006).3.2. PINK1-deficient b-cells display impaired calcium
homeostasis and elevated cytosolic calcium
Given the close link between intracellular calcium levels and
the stimulation of insulin secretion in pancreatic b-cells,
we assessed the basal levels of [Ca2þ]c in PINK1-deficient
b-cells. Two cellular systems were assessed: knockdown
(kd) mouse pancreatic b-cells (MIN6 cells) which had been
treated with mouse PINK1 (mPINK1) or scramble (Scr) con-
trol siRNA, and intact islets isolated from PINK1 WT and
KO littermates (aged six months). RT-PCR analysis of
PINK1 levels in both KO islets and in MIN6 cells treated with
mPINK1 siRNA showed a significant decrease in detecta-
ble levels of mPINK1 in both systems (figure 1b,c, n ¼ 4,
p , 0.003). [Ca2þ]c was measured using the Fura-2 indicator.
Upon initial examination, we noted that the basal intracellu-
lar [Ca2þ]c concentration in PINK1-deficient cells was
significantly higher compared with controls (1.04+0.05
Fura-2 ratio (n ¼ 86 cells) in PINK1 kd compared with
0.86+ 0.04 Fura-2 ratio in control (n ¼ 91); p , 0.001; figure
1d ). In agreement, the PINK1 KO intact islets also had a sig-
nificantly higher basal level of [Ca2þ]c compared with WT
controls (1.15+0.02 Fura-2 ratio (n ¼ 9 islets) in PINK1 KO
islets compared with 0.96+0.02 in WT control (n ¼ 10);
p , 0.001; figure 1e). We subsequently examined the effects
on [Ca2þ]c levels after glucose stimulation. Application of 5,
10 and 20 mM glucose to Scr control MIN6 cells and WT
islets induced a dose-dependent ‘peak-like’ increase in
[Ca2þ]c as expected (n ¼ 5 experiments; figure 1f and g,
respectively). By contrast, PINK1 kd MIN6 cells or
KO islets showed no increase in [Ca2þ]c when exposed to
5 mM glucose and demonstrated a significantly smaller
[Ca2þ]c increase in response to both 10 ( p , 0.01) and
20 mM ( p , 0.001) glucose (n ¼ 4 experiments; figure 1f
and g, respectively). Notably, the difference between basal
calcium levels in PINK1 kd cells and KO islets was com-
parable to the calcium signal induced in the control cells
and WT islets in response to the 5 mM glucose stimulus
(figure 1f,g). As previously mentioned, calcium influx in
b-cells, in response to glucose stimuli, is typically regulated
by Kþ-ATP channels. To determine whether the normal cal-
cium signalling pathway through the Kþ-ATP channels was
impaired by PINK1 deficiency, MIN6 cells and islets were
treated with 100 mM tolbutamide (which inhibits activa-
tion of Kþ-ATP channels and should induce a classical high
[Ca2þ]c influx). Application of tolbutamide induced com-
parable calcium signals between PINK1-deficient and
WT controls in both MIN6 cells and intact islets (figure 1f
and g, respectively). This suggests that, despite the
alteration in glucose-stimulated calcium influx, PINK1-
deficient b-cells have a normal calcium signal through the
Kþ-ATP-dependent pathway.
We have previously shown that PINK1 deficiency in neur-
ons induced high levels of cellular ROS through NADPH
oxidase [8,14]. To ascertain if the increased basal [Ca2þ]c in
PINK1-deficient b-cells was also induced by elevated levels
of cellular ROS through NADPH oxidase activity, the ability
of PINK1 kd b-cells to respond to glucose stimuli was reas-
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Figure 1. Assessment of cytosolic calcium levels in PINK1-deficient b-cells. (a) PINK1 expression in MIN6 cells and isolated PINK1 WT and KO islets compared with
WT midbrain. *p , 0.05 and **p , 0.005, Mann – Whitney U-test. (b) RT-PCR confirmation of PINK1 knockdown levels obtained via siRNA treatment. p , 0.005,
paired t-test. (c) RT-PCR confirmation of PINK1 levels in PINK1 WT and KO islets. p , 0.005, Mann – Whitney U-test. (d ) Basal levels of Fura-2 ratio in Scr control
versus PINK1 kd siRNA-treated cells. p , 0.005, paired t-test. (e) Basal levels of Fura-2 ratio in WT control versus PINK1 KO islets, p , 0.005, Mann – Whitney
U-test. ( f ) Representative traces showing measurement of Fura-2 ratio alteration induced by glucose stimuli in Scr control versus PINK1 kd cells. (g) Representative
traces measuring alteration of Fura-2 ratio in WT control versus PINK1 KO islets, respectively. p , 0.005, paired t-test. (h) Alteration of Fura-2 ratio in Scr control and
PINK1 kd cells with increasing glucose stimuli and improvement of PINK1 kd cell response with DPI or MnTBAP treatment. p , 0.005, paired t-test. (i) Alteration of
Fura-2 ratio in Scr control and PINK1 kd cells, but not Parkin kd, with increasing glucose stimuli and rescue of PINK1 kd cell response with PINK1-wt re-expression.








4diphenylene iodonium (DPI, n ¼ 3 experiments), and the
anti-oxidant MnTBAP (a ROS scavenger, n ¼ 3 experiments).
After treatment, PINK1 kd cells showed a significant
improvement in their ability to respond to 5, 10 and 20 mM
glucose, but this increase was not sufficient to restore the
levels back to those observed in control cells (figure 1h).
In PD, PINK1 is known to function upstream in the
same pathway as another PD-related protein called ‘Parkin’,
where overexpression of Parkin can compensate for PINK1
deficiency [15]. To confirm our observations were therefore
specific to loss of PINK1, we re-examined the effects on
intracellular calcium after knockdown of mouse Parkin via
siRNA and also performed rescue experiments in the
PINK1 kd cells by transfecting in either vector control,
human PINK1-wild-type (hPINK1-wt), human PINK1-
kinase dead (hPINK1-KD) or human Parkin (hParkin-wt).
Figure 1i shows that only expression of hPINK1-wt was
able to rescue the effects of the aberrant calcium signal in
PINK1 kd cells, suggesting that these effects are a direct con-
sequence of PINK1 deficiency and are dependent on PINK1
kinase activity (n ¼ 3, p , 0.05). Confirmation that PINK1
kd had no effect on endogenous Parkin levels and the effi-
ciency of siRNA-mediated Parkin knockdown are shown in
the electronic supplementary material, figure S1.3.3. Loss of PINK1 results in mitochondrial dysfunction
in b-cells
Under normal circumstances, application of glucose to cells
induces an increase in glucose metabolism, which, in turn,
increases the concentration of available mitochondrial sub-
strates [16]. The substrates are used by mitochondria, and
this increases a number of mitochondrial characteristics
such as the production of NADH and an increase in mito-
chondrial membrane potential (DCm) [17]. As PINK1 is
known to be essential for maintaining normal mitochondrial
function in neurons, we assessed mitochondrial function in
the islets. In our experiments, application of increasing con-
centrations of glucose induced a dose-dependent increase of
NADH autofluorescence in WT islets (n ¼ 12; figure 2a).
However, the application of the same glucose solutions
induced a significantly smaller response in PINK1-deficient
islets (n ¼ 10; figure 2a). A lower level of mitochondrial
substrates, such as NADH, in PINK1-deficient cells should
make them less sensitive to changes in DCm. To confirm
this, we assessed alterations in DCm in response to glucose
stimuli using rhodamine 123 (Rh123) [18]. Figure 2b shows
that application of 5, 10 and 20 mM of glucose induces a
step-like increase in DCm in WT islets which registers as
a decrease in Rh123 fluorescence. Application of the same
glucose solutions to PINK1 KO islets induced a significantly
smaller hyperpolarization in DCm. As a control, complete
depolarization of the cells was induced with 1 mM FCCP
and generated a maximal increase in Rh123 fluorescence.
Importantly, application of mitochondrial substrates such
as malate or methyl succinate induced a profound mito-
chondrial hyperpolarization in both cell types (figure 2c),
suggesting that the mitochondria in PINK1-deficient islets
are not damaged and have a fully functional response
when mitochondrial substrates are available. Considering
this, our results suggest that PINK1-deficient b-cells have
impaired glucose delivery or glycolysis.3.4. PINK1 deficiency impairs glucose uptake in b-cells
To determine whether glucose uptake was impaired in
PINK1-deficient b-cells, we used the fluorescent glucose ana-
logue 2-NBDG (which is used to monitor glucose uptake in
live cells) and repeated the experiment described above.
Our results show that at basal levels, the ability of PINK1
kd b-cells and intact KO islets to take up glucose is signifi-
cantly impaired compared with Scr control cells or WT
islets (47.8+ 3.9% of control, n ¼ 4 experiments; p , 0.001;
figure 2f and 42.4+ 3.1% of control islets; n ¼ 9; p , 0.001;
figure 2d, respectively). To ensure this alteration was not
due to altered expression of either the GLUT1 or GLUT2
transporters, the expression of both transporters was assessed
by western blot and found to be comparable between both
WT and PINK1 KO islets (figure 2e). Upon treatment with
DPI, PINK1-deficient cells and islets show a significant
improvement in their ability to take up glucose, suggesting
that increased ROS levels, through NADPH oxidase activity,
may underlie the abnormal [Ca2þ]c (from 47.8+3.9%
to 82.4+6.4%, n ¼ 69; p , 0.00001; figure 2f and from
42.4+3.1% to 77.2+4.1%, n ¼ 9 islets; p , 0.001; figure 2g).
Treatment of PINK1 kd cells with MnTBAP also significantly
improved glucose uptake (from 47.8+3.9% to 68.7+6.3%,
n ¼ 37; p , 0.005; figure 2f ). However, while DPI treatment
was able to rescue PINK1 kd glucose uptake back to levels
comparable to those observed in Scr cells, it could not rescue
the alteration in [Ca2þ]c to the same extent (compare figure 2f
with figure 1h). To confirm that inhibition of glucose uptake
was specifically due to loss of PINK1, we repeated the
2NDBG experiments in MIN6 cells after siRNA-induced
mouse Parkin kd and via rescue experiments in the PINK1
kd b-cells. The rescue experiments were done by transfecting
in either vector control, hPINK1-wt, hPINK1-KD or hParkin-
wt. Loss of Parkin was found to have no effect on glucose
uptake compared with vector or Scr control cells, and only
expression of hPINK1-wt was able to restore glucose uptake
in PINK1-deficient b-cells (figure 2h, n ¼ 42; p , 0.005).
Interestingly, incubation of Scr control cells with 0.5 mM
of DPI induced the opposite effect and demonstrated a
slight inhibition of glucose uptake (figure 2f ), suggesting
that ROS can be one of the regulators of this transporter.3.5. Loss of PINK1 increases basal levels of insulin
secretion
To determine the impact of PINK1 deficiency on insulin release,
we measured the level of insulin secreted by WT control and
PINK1 KO intact islets under low and high glucose conditions.
As expected, the WT islets secreted significantly more insulin
in response to the high 20 mM glucose stimulus than the low
2 mM stimulus (n ¼ 6; p , 0.05; figure 3a). By contrast, PINK1
KO islets secreted significantly higher levels of insulin than
their WT counterparts in response to 2 mM glucose and, nota-
bly, the level secreted was comparable to the WT islet response
to 20 mM glucose (n ¼ 6; p , 0.05; figure 3a). When exposed
to high glucose, the PINK1 KO islets also secreted significantly
more insulin compared with those observed under low glucose
conditions (n ¼ 6; p , 0.005; figure 3a). This confirms our
previous observations in MIN6 cells and intact islets demon-
strating that PINK1-deficient cells can still respond to high
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Figure 2. PINK1 deficiency impairs mitochondrial function and glucose-sensing. (a – d) Representative traces measuring alteration of NADH autofluorescence,
rhodamine 123 fluorescence and 2-NBDG uptake in WT control versus PINK1 KO islets, respectively. p , 0.005, Mann – Whitney U-test. (e) GLUT1 and GLUT2
transporter expression in WT and PINK1 KO islets. ( f ) Alteration of 2-NBDG uptake rate in Scr control versus PINK1 kd cells at basal levels and after DPI or
MnTBAP treatment. p , 0.001, p , 0.00001 and p , 0.005, respectively, paired t-test. (g) Alteration of 2-NBDG uptake rate in WT control versus PINK1 KO
intact islets at basal levels and after DPI treatment. p , 0.005 and p , 0.001, respectively; Mann – Whitney U-test. (h) Alteration of 2-NBDG uptake rate in
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Figure 3. PINK1 KO mice suffer from glucose tolerance and altered insulin secretion in vivo. (a) Concentration of insulin secreted by WT and KO PINK1 isolated islets under
low and high glucose stimuli. p , 0.005, Mann – Whitney U-test. (b) Residual concentration of insulin extracted from WT and KO islets. p , 0.05, Mann – Whitney U-test.
(c,d) Basal blood glucose concentrations in PINK1 WT and KO mice in response to random feeding or overnight starvation, respectively. (e) Comparison of body weight
between PINK1 WT and KO animals. ( f ) Response of PINK1 WT and KO animals to a GTT. Two-way ANOVA with Bonferroni multiple comparison test with repeated
measures. p . 0.005, Mann – Whitney U-test. (g) Response of PINK1 WT and KO animals to an ITT. (h) Assessment of blood insulin levels in PINK1 WT and KO animals








7the difference in insulin secretion between WT and PINK1 KO
islets was due to altered total levels of insulin, the residual insu-
lin was extracted from the islets by acid ethanol and measured.
Notably, the total concentration of insulin (secreted plus
extracted) was comparable between WT and PINK1 KO islets
(figure 3b, n ¼ 6; p , 0.05).
As the final stage of our investigation, we used six
month old male PINK1 WT and KO mice to assess the effect
of PINK1 deficiency on islet function in vivo. Blood glucose
levels of both PINK1 WT and KO mice showed no discernable
differences after random feeding or 16 h starvation (figure 3c,d).
In addition, body weight was comparable (figure 3e) and pre-
liminary observations indicated no difference in food or water
consumption (data not shown). A glucose tolerance test
(GTT) revealed that while PINK1 WT and KO mice initially
show a comparable increase in blood glucose levels, the levels
in PINK1 KO mice peak at a lower level and decrease signifi-
cantly faster than the WT littermates (figure 3f, p , 0.05).
However, the response to an insulin tolerance test (ITT) was
comparable and showed an initial drop in blood glucose
levels followed by recovery (figure 3g). A glucose-stimulated
insulin secretion (GSIS) experiment revealed that, as in our
islet experiments, PINK1 KO mice have a higher basal level of
insulin in the bloodstream (figure 3h). This, however, did not
reach significant levels compared with WT. Upon injection of
glucose, the PINK1 KO mice were initially stimulated to secrete
insulin into the blood, but after 3 min, the level secreted was
lower than that observed in WT animals (figure 3f). At 7 min
post-injection, the blood insulin levels in the PINK1 KO mice
had returned to baseline, whereas the WT blood insulin
levels, although reduced, remained significantly higher than
the basal reading ( p , 0.05). However, insulin secretion in the
KO animals increased to levels comparable to WT littermates
20 min post-injection (figure 3f). These combined results
suggest that PINK1 deficiency results in improved glucose tol-
erance in vivo and also indicate that, in vivo, there appears to be a
trend towards increased basal blood insulin levels with a
reduced initial secretion response. In addition to these studies,
RT-PCR analysis of several key genes involved in glucose
homeostasis (GSK3b, Pecam1, HNF1a, HNF4a, ECAD, GCK,
Neurod1, Nkx6.1, FoxA2, PDK1, Pfkp, ALDOB, GAPDH and
AKT) revealed that while HNF4a was downregulated in
PINK1 KO islets, GCK, Neurod1, Nkx6.1, PDK1 and FoxA2
were all upregulated compared with WT age-matched con-
trols (figure 4a–e and f, respectively, n ¼ 4; for HNF4a and
GCK p , 0.0006, for FoxA2 and PDK1 p , 0.004, for Nkx6.1
and Neurod1 p , 0.02). The remaining genes examined
showed no significant alteration between genotypes (electronic
supplementary material, figure S2).4. Discussion
Mutations within the PINK1 gene have been extensively
shown to be responsible for early-onset autosomal recessive
PD [7,19]. PINK1 is a mitochondrial protein, and there is
now overwhelming evidence that mitochondrial dysfunction
is a key player in PD [20,21]. However, while the death of
dopaminergic neurons in the substantia nigra of the brain is
the most prominent disease presentation in patients with
PINK1 mutations, recent reports have implicated PINK1
gene dysfunction or dysregulation as a potential risk factor
for the metabolic disorder T2DM [11,12]. The aim of thisstudy was to assess the functional significance of PINK1
deficiency in b-cells and islets. Our results show that in the
pancreas, normal b-cell function is impaired through
PINK1 deficiency leading to higher basal levels of insulin
secretion in vitro and a trend towards increased basal
plasma insulin in vivo. Using MIN6 cells and intact islets
from PINK1 KO mice, we have demonstrated that this
increase is independent of glucose levels and is instead
induced by higher basal calcium levels in the cells. We have
additionally shown that glucose uptake is significantly inhib-
ited in PINK1 kd b-cells and KO islets compared with WT
controls. This leads to impaired mitochondrial function and
calcium signalling in response to low glucose concentrations.
Through bypassing the glucose metabolism pathway and
simply supplying the islets with alternative mitochondrial
substrates, for example, malate and methyl succinate, we
have shown that the normal b-cell pathway to insulin
secretion, including regulation of calcium influx through
the Kþ-ATP channel, is not impaired by a PINK1 deficit.
Together, these data indicate that the glucose transporter is
inhibited, but not fully impaired, in these cells. In support
of this, our combined data show that high concentrations of
glucose can still stimulate additional insulin release from
PINK1-deficient cells through the glucose stimulation path-
way. Loss of PINK1 function therefore appears to uncouple
GSIS during low levels of glucose stimuli. In addition,
through rescue experiments using inhibitors or anti-oxidants,
we have shown that inhibition of the glucose transporter is
due to ROS production by NADPH oxidase. One intriguing
result obtained was the mild inhibition of the glucose trans-
porter in WT b-cells with the NADPH oxidase inhibitor,
suggesting that this enzyme is essential for normal maximal
function of the glucose transporter in these cells.
Our in vivo results demonstrate that the PINK1 KO ani-
mals have improved glucose tolerance. One explanation for
these findings is that the increased basal insulin level is suffi-
cient to stimulate the presentation of glucose transporters
at the cell surface [22] and therefore primes the peripheral tis-
sues to take up glucose from the blood at a faster rate. While
our in vitro data would support this hypothesis, the insulin
increase did not reach significance in our in vivo study
when compared with WT controls. This could be owing to
compensation mechanisms keeping insulin levels below
detrimental physiological levels or owing to experimental
procedure. We did, however, observe a significant upregula-
tion of both GCK and PDK1 transcription (known to be
regulated by insulin), suggesting that the levels of insulin
in vivo may still be sufficient to elicit an abnormal physiological
effect. Interestingly, we also observed an upregulation of
Neurod1 and NKx6.1, which are known to increase transcrip-
tion of the insulin gene [23,24] and a reduction in HNF4a
transcription, known to occur during hyperinsulinemia
(excess levels of insulin in the blood). However, these alterations
could be due to compensatory/homeostatic mechanisms
attempting to regulate insulin levels in the blood. The upregu-
lation of FoxA2 could also account for the observed reduction
of HNF4a transcription, as these are reportedly linked [25].
Finally, we cannot exclude additional factors such as a
reduction in hepatic gluconeogenesis that could result in the
in vivo improved glucose tolerance. While we have yet to ident-
ify the underlying in vivo mechanism behind the increased
blood glucose clearance, the results of the ITT indicate that

































































































































































































































Figure 4. PINK1 mice display altered glucose homeostasis gene transcription in intact islets. (a – f ) RT-PCR assessment of gene transcription in PINK1 KO versus WT
islets showing a downregulation of HNF4a and an upregulation of GCK, Neurod1, Nkx6.1, PDK1 and FoxA2, respectively. p , 0.05, Mann – Whitney U-test.





In the broader setting of T2DM, the predominant cause
of T2DM is frequently insulin resistance. It is therefore plaus-
ible that the reduced transcription of PINK1, reported in
T2DM patients by Scheele et al. [11], could be a compensatory
mechanism attempting to increase basal insulin secretion, so
the peripheral tissues respond to a glucose stimulus. Current
T2DM therapeutics, specifically sulfonylureas, work by this
mechanism. However, we cannot exclude the possibility
that the reduction in PINK1 levels, through inducing
increased levels of basal insulin secretion, could contribute
to the development of insulin resistance over time. In order
to determine whether the reduced PINK1 levels reported by
Scheele and colleagues are a cause or effect of T2DM, studies
using inducible b-cell-specific PINK1 KO studies in mice is
required. Furthermore, it would be of interest to determinethe effect of the N521T variation on PINK1 transcription
levels, protein levels and function to see if this mutation
results in reduced levels of functional PINK1.
In the context of PD, a study reported that 50–80% of PD
patients exhibit abnormal glucose tolerance [26]. Notably,
while this study was conducted nearly two decades ago,
there is now increasing evidence that T2DM and PD may com-
monly co-occur [11,12], and a retrospective study of T2DM
patients reports that diabetes is associated with a significantly
higher risk of developing PD [27]. Given the link between
the regulation of insulin and dopamine in the body, this is per-
haps not surprising. Specifically, insulin resistance has been
reported to reduce both nigrostriatal dopamine release and
dopamine clearance in the brain [28], whereas insufficient insu-




9tyrosine hydroxylase mRNA in the substantia nigra [29]. Insu-
lin has also been reported to have multiple neuroprotective
functions in the brain [30], and more recently, increased insulin
levels have been shown to directly affect the firing rate of
mouse midbrain tyrosine hydroxylase positive neurons—the
loss of which results in PD in humans [31]. These combined
effects of insulin dysregulation on the dopaminergic neuronal
system may partly explain why diabetes is a risk factor for PD,
but our finding that a deficiency of the PD-associated protein
PINK1 can directly alter insulin secretion from islets suggests
that these two diseases could be linked mechanistically.
The interconnected signalling effects of both insulin and
dopamine therefore need to be addressed in the context of
patient treatment and management. When compared with
patients who suffered from PD alone, PD patients with dia-
betes were found to have accelerated progression of both
motor and cognitive neurodegenerative symptoms [32,33].
Interestingly, bromocriptine (a potent dopamine receptor
agonist) has been shown to improve insulin sensitivity in
rodent studies [34], whereas exposure of animals to levodopa
(a common PD therapeutic) induces an increase in blood
glucose levels [35]. More recently, the diabetic drug Actos
(pioglitazone) was highlighted as a potential PD therapeutic,
because the drug activates the PGC-1a protein pathway,
and genes regulated by PGC-1a are known to be present at
abnormally low levels in PD brain [36]. It will therefore be
of significant interest to the PD field to assess additional
established diabetic therapeutics as novel PD treatments
and whether aggressive treatment of T2DM can reduce the
incidence of PD in general.5. Material and methods
5.1. Animals
PINK1-deficient mice, originally generated by Lexicon
Genetics Inc. (The Woodlands, TX), were obtained under
MTA through Julian Downward, CRUK, London. Mice were
maintained on a 12 L : 12 D cycle with free access to water
and food. Animal husbandry and experimental procedures
were performed in full compliance with the United Kingdom
Animal (Scientific Procedures) Act of 1986 and with approval
of the University College London Animal Ethics Committee.
Animals were genotyped by PCR amplification of ear biopsy
material in the following manner: genomic DNA was isolated
from biopsy tissue using the extract-N-Amp tissue PCR kit
(Sigma) and amplified with primers PINK1–26 (50-CTGCC
CTCAGGGTCTCTAATGC-30), PINK1–27 (500-GGAAGGAG
GCCATGGAAATTGT-30) and Neo (50-GCAGCGCATCGC
CTTCTATC-30). PCR conditions were 948C denaturation—
45 s, 608C annealing—45 s and 728C extension—45 s. This
cycle was repeated 30 times.
5.2. MIN6 cell culture and siRNA transfections
Murine MIN6 b-cells were routinely cultured at 378C with 5%
CO2 in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum (FBS) Gold (PAA Laboratories).
For imaging experiments, MIN6b-cells were plated at a density
of 300 000 onto poly-L-lysine-coated coverslips and left
overnight to adhere. Cells were then transfected with either
mouse PINK1 siRNA or scrambled control siRNA (siGENOMEpools, Dharmacon) as per the manufacturer’s instructions and
incubated for 48 h. One hour prior to imaging, cells were cul-
tured in HEPES-buffered salt solution (HBSS) supplemented
with 20 mmol l21 HEPES and 2 mmol l21 D-glucose.
5.3. Islet cell isolation
Mice were killed by cervical dislocation, and islet cells were
isolated as previously described [37]. Briefly, the common
bile duct was cannulated and its duodenal end occluded
by clamping. Liberase solution (2 ml at 0.25 mg ml21 in
Krebs–Ringer buffer solution with 100 U ml21 penicillin/
100 mg ml21 streptomycin (Pen/Strep)) was injected into the
duct to distend the pancreas. The pancreas was then removed,
placed in a 15 ml falcon containing 2.5 ml Liberase solution
and incubated at 378C for 12 min. Cold quench buffer (8 ml)
was added, and the tube was shaken vigorously to break up
the tissue. The dissociated tissue solution was then strained
through a 1 mm diameter wire mesh filter into a 50 ml
falcon, an additional 10 ml of quench buffer was added and
the sample was centrifuged at 1000 r.p.m. for 1 min at 48C.
The supernatant was discarded, and the cell pellet containing
the islets was resuspended in 20 ml quench buffer. The cen-
trifugation step was repeated twice. After the final spin, the
sides of the falcon tube were dried, 15 ml of cold Ficoll solution
(15 ml) was added and the sample was vortexed to resuspend
the cells. Cold Ficoll solution was carefully added to the
tube followed by 15 ml of cold quench buffer (again added
carefully to create a Ficoll gradient). Samples were then centri-
fuged at 2510 r.p.m. for 22 min at 108C. The supernatant was
carefully removed and passed through a 70 mm filter to retain
intact islets. Collected cells were washed three times in 20 ml
quench buffer before being rinsed into a 10 cm cell culture
dish with RPMI GlutaMAX supplemented with 25 mM
HEPES, 10% FBS, Pen/Strep. Islets of similar sizes were either
allocated in batches of five into 96-well plates for static insulin
secretion experiments or plated onto poly-L-lysine-coated
coverslips and left to adhere overnight for imaging studies.
5.4. Imaging studies
Fluorescence measurements were obtained on an epifluores-
cence inverted microscope equipped with a 20/0.5 fluorite
objective. Emitted fluorescence light was reflected through a
filter to a cooled CCD camera (Retiga, QImaging, Canada)
and digitized to 12-bit resolution. All imaging data were col-
lected and analysed using software from Andor (Belfast, UK).
For measurements of [Ca2þ]c, cells were loaded for
30 min at room temperature with 5 mM of Fura-2 AM in
combination with 0.005% pluronic acid in HBSS composed
of 156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM
KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM HEPES
(pH adjusted to 7.35 with NaOH). DPI was used at a concen-
tration of 0.5 mM and MnTBAP at 200 mM. Traces were
normalized to the maximal value of calcium concentration
induced upon exposure to ionomycin.
For glucose uptake experiments, the uptake of the fluorescent
glucose homologue 2-NBDG (Invitrogen) was measured by the
addition of 40 nM 2-NBDG in the presence of 0.25 mM glucose
during a period of continuous imaging.
For measurements of DCm, cells were loaded with
2.6 mM (equivalent to 1 mg ml21; Molecular Probes) Rh123
for 15 min at room temperature, and the dye was washed
rsob.royalso
10prior to the experiment. Under these loading conditions,
Rh123 is non-toxic and gives a reliable and reproducible
measure of DCm through the ‘dequench’ of mitochondrial
fluorescence, and thus an increase in the Rh123 signal reflects
mitochondrial depolarization.cietypublishing.org
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Islet cell insulin secretion experiments were conducted as fol-
lows. Islets were isolated from animals as described above
and cultured in RPMI 1640 GlutaMAX media supplemented
with 25 mM HEPES, 10% FCS and Pen/Strep. The following
day, islets were transferred to a fresh 35 mm culture dish,
and medium was replaced with low glucose secretion buffer
(1 KRB solution, 10 mM HEPES, 1 mM CaCl2, 0.5% BSA
and 2 mM glucose). Islets were incubated at 378C for 1 h.
Five islets of similar size were transferred in 10 ml into 1 well
of a 96-well plate. A minimum of six wells per animal subject
was plated. The islets were then incubated in 150 ml of low or
high glucose secretion buffer (recipe as described above but
20 mM glucose was supplied in the high glucose secretion
buffer) for 1 h at 378C. The 96-well plate was placed on ice
and centrifuged at 1000 r.p.m. for 1 min. One hundred millili-
tres of the supernatant was removed and frozen for assessment.
The residual medium was aspirated, and 100 ml of ice-cold acid
ethanol was added to the wells and the plate was frozen over-
night at 2208C to extract the remaining insulin. Supernatant
and acid ethanol samples were assessed for insulin content
using the Millipore insulin ELISA.5.6. Glucose tolerance test and glucose-stimulated
insulin secretion
Male mice were fasted overnight prior to test initiation. The
GTT and GSIS procedures were performed as previously
described [38]. Briefly, a tail snip was performed, basal blood
glucose levels were measured using glucose test strips
(Bauers) and blood was collected to later assess basal insulin
levels. Mice were then weighed, injected with 2 g kg21 fresh
glucose solution and blood glucose was measured at 3, 7, 15,
20, 30, 60, 90 and 120 min time points post-injection. Additional
blood samples to assess insulin levels were collected at 3, 7 and
20 min during the procedure. Blood samples to assess insulin
levels were kept on ice before centrifugation at 5130 r.p.m.
(300g) for 15 min at 48C. The supernatant was retained and
analysed by insulin ELISA.5.7. Insulin tolerance test
Male mice were left for three weeks to recover from the GTT
and GSIS procedure prior to the ITT test. The tail snip wound
scab was removed, and basal blood glucose was measured as
described in the GTT procedure. Male mice were reweighed
and injected with a stock solution of human recombinant
insulin (0.185 U ml21 in saline). The amount of insulin
injected per animal was calculated as follows: body weight
(g)  4 ¼ ml volume of stock insulin solution injected by IP.
Blood glucose levels were then assessed at 15, 30, 60, 90
and 120 min post-injection using the glucose test strips as pre-
viously mentioned.
5.8. Insulin ELISA
Static secreted and blood plasma insulin levels were assessed
by ELISA using the rat insulin kit (Millipore) as per the man-
ufacturer’s instructions.
5.9. RT-PCRs
SYBR Green RT-PCRs were performed using SYBR Select
master mix (Invitrogen) and performed on a Corbett Life
Sciences Rotor-Gene 6000 platform. Validated mouse RT-PCR
primer sequences were obtained via PrimerBank (http://pga.
mgh.harvard.edu/cgi-bin/primerbank) and ordered from
Invitrogen. PCR conditions were 958C hold for 5 min, 958C
for 15 s followed by 608C for 45 s for 45 cycles, then a melt.
The specific primer sequences used can be found in the elec-
tronic supplementary material, table S1. All data were
normalized to two housekeepers: HPRT1 and cyclophilinA.
5.10. Statistics
Data are presented as mean+ s.e.m., unless otherwise stated.
Statistics were performed using a combination of ORIGIN
PRO, GRAPHPAD (PRISM) and Microsoft EXCEL software.
Paired t-tests were performed on all MIN6 experiments, the
Mann–Whitney U-test was performed on all isolated islet
studies and two-way ANOVAs with Bonferroni multiple
comparison test with repeated measures were performed
for in vivo studies. Values of p , 0.05 are denoted as *
whereas ** represents p , 0.005, unless stated otherwise.
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